Incyte Corporation
General ticker "INCY" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $17.9B (TTM average)
Incyte Corporation follows the US Stock Market performance with the rate: 44.3%.
Estimated limits based on current volatility of 2.2%: low 112.55$, high 117.53$
Factors to consider:
- Earnings expected soon, date: 2026-07-28 bmo
- Company included in S&P500 list
- Total employees count: 2844 (+8.7%) as of 2025
- US accounted for 94.3% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Failure to commercialize drug compounds, Regulatory and compliance, Commercialization challenges, Product liability, Intellectual property risks
- Price in estimated range
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [80.92$, 123.02$]
- 2026-12-31 to 2027-12-31 estimated range: [82.52$, 125.78$]
Financial Metrics affecting the INCY estimates:
- Negative: with PPE of 14.7 at the end of fiscal year the price was high
- Positive: Operating profit margin, % of 26.12 > 18.40
- Positive: 6.62 < Operating cash flow per share per price, % of 7.26
- Positive: Inventory ratio change, % of 0.56 <= 0.80
- Positive: Return on assets ratio (scaled to [-100,100]) of 15.61 > 6.02
- Positive: Interest expense per share per price, % of 0.01 <= 0.74
- Positive: Investing cash flow per share per price, % of -0.53 > -0.60
- Negative: negative Industry operating cash flow (median)
Short-term INCY quotes
Relationship graph
Long-term INCY plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $3,695.65MM | $4,241.22MM | $5,383.49MM |
| Operating Expenses | $3,075.12MM | $4,179.85MM | $3,868.63MM |
| Operating Income | $620.52MM | $61.37MM | $1,514.86MM |
| Non-Operating Income | $213.69MM | $255.26MM | $149.59MM |
| Interest Expense | $2.55MM | $2.28MM | $2.43MM |
| R&D Expense | $1,627.59MM | $2,606.85MM | $2,050.15MM |
| Income(Loss) | $834.22MM | $316.63MM | $1,664.45MM |
| Taxes | $236.62MM | $284.01MM | $377.80MM |
| Net Income(Loss)* | $597.60MM | $32.62MM | $1,286.65MM |
| Stockholders Equity | $5,189.84MM | $3,447.63MM | $5,167.48MM |
| Inventory | $62.97MM | $58.87MM | $101.06MM |
| Assets | $6,782.11MM | $5,444.32MM | $6,957.97MM |
| Operating Cash Flow | $496.49MM | $335.34MM | $1,413.50MM |
| Capital expenditure | $47.49MM | $86.26MM | $58.87MM |
| Investing Cash Flow | $-207.68MM | $157.52MM | $-102.61MM |
| Financing Cash Flow | $-20.03MM | $-2,021.55MM | $101.04MM |
| Earnings Per Share** | $2.67 | $0.16 | $6.59 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.